P387 Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars

Ruiz-Agüello, M.B.; Maguregui, Ainara; Martínez, A. Pérez; Nagore, Daniel

doi:10.1093/ecco-jcc/jjx180.514

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several enzyme-linked immunosorbent assay (ELISA) methods are available to allow for easy and efficient quantification of infliximab serum levels and adjustment of dose during TDM [41]. Studies have shown that commercially available assays used in patients receiving reference infliximab can also be used with confidence to monitor drug levels in patients treated with the infliximab biosimilars CT-P13 or SB2 [41][42][43][44]. Assays such as the Promonitor-ANTI-IFX kit can also be used to monitor ADAs in patients receiving reference infliximab, CT-P13 or SB2 [42].…”

Section: Therapeutic Drug Monitoring and Immunogenicitymentioning

confidence: 99%

Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach

Peyrin–Biroulet

Danese

Cummings

et al. 2019

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Introduction: The purpose of this review is to highlight the role of biosimilars in early treatment in IBD and introduce ways to facilitate a patient-centric switching process through multidisciplinary approach.Areas covered: We summarize existing scientific literature related to the role of biosimilars in inflammatory bowel disease in terms of early treatment and cost-saving and implementing switching process. Expert opinion: Use of anti-TNF biosimilars in patients has the potential for large drug-acquisition costsaving, which can be reinvested into early treatment. Managed switched programs for adalimumab can add further benefits in the future.

show abstract

Section: Therapeutic Drug Monitoring and Immunogenicitymentioning

confidence: 99%

Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach

Peyrin–Biroulet

Danese

Cummings

et al. 2019

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

show abstract

Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade

Iliás

Szántó

Gönczi

et al. 2019

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

To view, print and annotate your content you will need Adobe Reader version 9 (or higher). This program is freely available for a whole series of platforms that include PC, Mac, and UNIX and can be downloaded from http://get.adobe.com/reader/. The exact system requirements are given at the Adobe site:. Note: Please do NOT make direct edits to the PDF using the editing tools as doing so could lead us to overlook your desired changes. Rather, please request corrections by using the tools in the Comment pane to annotate the PDF and call out the changes you are requesting. If you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. PDF ANNOTATIONS Adobe Reader version 9 Adobe Reader version X and XI When you open the PDF file using Adobe Reader, the Commenting tool bar should be displayed automatically; if not, click on 'Tools', select 'Comment & Markup', then click on 'Show Comment & Markup tool bar' (or 'Show Commenting bar' on the Mac). If these options are not available in your Adobe Reader menus then it is possible that your Adobe Acrobat version is lower than 9 or the PDF has not been prepared properly. (Mac) PDF ANNOTATIONS (Adobe Reader version 9) The default for the Commenting tool bar is set to 'off' in version 9. To change this setting select 'Edit | Preferences', then 'Documents' (at left under 'Categories'), then select the option 'Never' for 'PDF/A View Mode'.

show abstract

P387 Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars

Cited by 2 publications

References 0 publications

Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach

Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach

Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade

Contact Info

Product

Resources

About